Merck & Bangs both had revenue deals - but the enhanced products were listed at the "premium" end of things thus sales were slow. Early on the SSH medical devices business was released to concentrate efforts on Mix&Go R&D.
AMG products are currently available via distribution agreements (& with Genodx Sinopharm shortly). But those products could be better leveraged.
Ellueme deal will have terms - but the products will be determined ready market when GSK say they are(JIMHO).
AnteoBind Battery deals will require field expertise and negotiation experience- with the possibility of multiple deals (generic and many custom blends) across the 3 solutions they are working on (see updates - or they may have more in tomorrow's Quarterly).
Ann: Strengthens Executive Team with CEO Appointment, page-125
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
-0.002(8.33%) |
Mkt cap ! $54.31M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.2¢ | $12.59K | 542.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 487271 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 200000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ADO (ASX) Chart |